Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anodyne Therapy reimbursement support

This article was originally published in The Gray Sheet

Executive Summary

More than 1,000 patients and physical therapists submitted comments to CMS in support of national coverage for the Anodyne Therapy infrared device to treat peripheral neuropathy during the comment period ended Feb. 26. Anodyne contacted customers to encourage them to voice their support, a strategy that it has successfully used to reverse previous local coverage denials. In the internally generated national coverage request, CMS cites concerns from an FDA warning letter to the manufacturer as an impetus for considering national non-coverage of the device (1"The Gray Sheet" Feb. 6, 2006, p. 5). CMS plans to issue a proposed decision by July 26...

You may also be interested in...

In Rare Move, CMS Cites FDA Warning Letter In National Coverage Request

CMS' internally-generated national coverage request for infrared therapy devices uncharacteristically refers to a recent FDA warning letter to manufacturer Anodyne Therapy

Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar

Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.

UK MHRA Updates Assistive Tech And Borderline Regulations

Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts